New: Introducing the Finviz Crypto Map

Learn More
Last Close
Jul 16 03:44PM ET
18.60
Dollar change
+0.65
Percentage change
3.61
%
Index- P/E9.06 EPS (ttm)2.05 Insider Own- Shs Outstand25.79M Perf Week1.64%
Market Cap446.96M Forward P/E- EPS next Y-5.42 Insider Trans- Shs Float- Perf Month-3.38%
Enterprise Value93.77M PEG- EPS next Q-2.04 Inst Own1.63% Short Float- Perf Quarter7.51%
Income52.55M P/S93.51 EPS this Y-345.71% Inst Trans-55.69% Short Ratio0.98 Perf Half Y-11.77%
Sales4.78M P/B1.16 EPS next Y-5.04% ROA8.11% Short Interest0.00M Perf YTD0.76%
Book/sh16.08 P/C1.21 EPS next 5Y- ROE11.96% 52W High25.00 -25.60% Perf Year-36.41%
Cash/sh15.35 P/FCF- EPS past 3/5Y- -32.37% ROIC12.24% 52W Low13.30 39.85% Perf 3Y-62.04%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-34.76% -13.21% Gross Margin25.70% Volatility1.95% 2.72% Perf 5Y-
Dividend TTM- EV/Sales19.62 EPS Y/Y TTM189.10% Oper. Margin-2831.14% ATR (14)0.64 Perf 10Y-
Dividend Ex-Date- Quick Ratio9.33 Sales Y/Y TTM43.67% Profit Margin1098.86% RSI (14)56.59 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio9.33 EPS Q/Q345.52% SMA204.25% Beta1.11 Target Price56.96
Payout0.00% Debt/Eq0.05 Sales Q/Q2416.84% SMA503.87% Rel Volume0.40 Prev Close17.95
Employees- LT Debt/Eq0.04 EarningsApr 30 BMO SMA200-2.50% Avg Volume3.90K Price18.60
IPONov 16, 2020 Option/ShortNo / Yes EPS/Sales Surpr.- - Trades Volume1,512 Change3.61%
Date Action Analyst Rating Change Price Target Change
Sep-09-24Resumed Leerink Partners Outperform $58 → $45
Today 02:00AM
Jul-08-25 12:45PM
Jun-26-25 02:00AM
Jun-16-25 12:59PM
May-22-25 07:00AM
05:15PM Loading…
May-20-25 05:15PM
May-09-25 07:00AM
May-02-25 09:00PM
May-01-25 07:00AM
Apr-30-25 07:56PM
02:00AM
Apr-23-25 02:00AM
Apr-09-25 02:00AM
Apr-07-25 12:16PM
Mar-11-25 07:05AM
07:27AM Loading…
Feb-25-25 07:27AM
Feb-12-25 07:05AM
Jan-27-25 02:00AM
Jan-10-25 07:15AM
Jan-09-25 07:00AM
Jan-08-25 07:00AM
Jan-06-25 02:00AM
Dec-16-24 11:41AM
02:00AM
Dec-11-24 07:05AM
Dec-09-24 02:00AM
Nov-20-24 07:05AM
Nov-18-24 04:49PM
Nov-05-24 07:05AM
Oct-30-24 07:00AM
07:40AM Loading…
Oct-21-24 07:40AM
02:00AM
Oct-09-24 06:44PM
02:00AM
Oct-01-24 07:00AM
Sep-30-24 06:52AM
Sep-27-24 02:00AM
Sep-06-24 02:00AM
Aug-28-24 02:01AM
Aug-22-24 02:00AM
Aug-21-24 02:00AM
Aug-13-24 07:05AM
Jul-23-24 08:26AM
Jun-24-24 12:00PM
02:00AM
Jun-20-24 02:00AM
Jun-18-24 07:05AM
Jun-13-24 01:15PM
Jun-06-24 12:38PM
May-29-24 08:09AM
May-23-24 07:00AM
May-21-24 07:05AM
May-20-24 06:35AM
02:00AM
May-09-24 07:05AM
May-07-24 07:05AM
Apr-30-24 08:37AM
Apr-25-24 05:22AM
Apr-18-24 02:00AM
Apr-16-24 07:00AM
Apr-11-24 07:00AM
Apr-09-24 08:19AM
02:00AM
Apr-02-24 08:50AM
Mar-19-24 03:00AM
Mar-18-24 09:52AM
Mar-13-24 07:00AM
Feb-27-24 07:00AM
02:00AM
Feb-15-24 09:35AM
Jan-03-24 07:00AM
Dec-22-23 09:13AM
Dec-20-23 02:00AM
Dec-07-23 06:00AM
Nov-29-23 10:17AM
Nov-17-23 02:00AM
Nov-14-23 02:00AM
Oct-17-23 02:00AM
Oct-11-23 07:00AM
Oct-04-23 07:05AM
Sep-28-23 07:38AM
Sep-27-23 02:05AM
Aug-30-23 01:04AM
Aug-22-23 02:00AM
Aug-01-23 07:00AM
Jun-21-23 07:00AM
Jun-13-23 12:40PM
May-24-23 07:00AM
May-09-23 02:00AM
May-04-23 02:00AM
Apr-29-23 01:23AM
Apr-25-23 06:50AM
Apr-17-23 07:05AM
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others. The Internal segment focuses on immunological, fibrotic, and lymphatic system mechanisms. The Controlled Founded Entities segment is composed of the group's subsidiaries that are currently consolidated operational subsidiaries that either have or have plans to hire independent management teams and currently have already raised, or are currently in the process of raising, third-party dilutive capital. The Non-Controlled Founded Entities segment includes companies wherein the group no longer holds majority voting control as a shareholder and no longer has the right to elect a majority of the members of the subsidiaries' Board of Directors. The Parent Company and Other segment represents activities that are not directly attributable to the operating segments, such as the activities of the parent, corporate support functions and certain research and development support functions that are not directly attributable to a strategic business segment as well as the elimination of intercompany transactions. The company was founded by Robert S. Langer Jr., Bennett M. Shapiro, and Daphne Zohar on May 8, 2015 and is headquartered in Boston, MA.